Last reviewed · How we verify

Standard of care plus pembrolizumab

The Netherlands Cancer Institute · Phase 3 active Small molecule

Standard of care plus pembrolizumab is a PD-1 inhibitor Small molecule drug developed by The Netherlands Cancer Institute. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma. Also known as: KEYTRUDA.

Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.

Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.

At a glance

Generic nameStandard of care plus pembrolizumab
Also known asKEYTRUDA
SponsorThe Netherlands Cancer Institute
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By binding to PD-1, pembrolizumab prevents the PD-1 ligands (PD-L1 and PD-L2) from interacting with PD-1, thereby releasing the brakes on the immune system and allowing it to attack cancer cells. This mechanism is thought to be particularly effective in cancers with high levels of PD-L1 expression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of care plus pembrolizumab

What is Standard of care plus pembrolizumab?

Standard of care plus pembrolizumab is a PD-1 inhibitor drug developed by The Netherlands Cancer Institute, indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.

How does Standard of care plus pembrolizumab work?

Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.

What is Standard of care plus pembrolizumab used for?

Standard of care plus pembrolizumab is indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma, Renal cell carcinoma, Classical Hodgkin lymphoma.

Who makes Standard of care plus pembrolizumab?

Standard of care plus pembrolizumab is developed by The Netherlands Cancer Institute (see full The Netherlands Cancer Institute pipeline at /company/the-netherlands-cancer-institute).

Is Standard of care plus pembrolizumab also known as anything else?

Standard of care plus pembrolizumab is also known as KEYTRUDA.

What drug class is Standard of care plus pembrolizumab in?

Standard of care plus pembrolizumab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Standard of care plus pembrolizumab in?

Standard of care plus pembrolizumab is in Phase 3.

What are the side effects of Standard of care plus pembrolizumab?

Common side effects of Standard of care plus pembrolizumab include Pneumonitis, Hypothyroidism, Hyperthyroidism, Diarrhea, Colitis, Arthralgia.

What does Standard of care plus pembrolizumab target?

Standard of care plus pembrolizumab targets PD-1 and is a PD-1 inhibitor.

Related